PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile | PTCT Stock NewsStockTitan·1 day ago, 11:00 PMPTCT+3.39%
PTC Therapeutics Director Michael Schmertzler sells 24,000 shares for $1.73 millionPUBT·Aug 21 at 04:20 PMPTCT+3.39%
PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding disposes of 2,813 common shares worth $204,863.91PUBT·Aug 19 at 04:20 PMPTCT+3.39%
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction DealMarket Beat·Aug 16 at 10:01 AMPTCT+3.39%
PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'benzinga_article·Aug 13 at 11:28 AMPTCT+3.39%
Sangamo selects winning bids in Chapter 11 asset auction for USD 163.55 million cash at closePUBT·Aug 12 at 03:28 PMSGMOQ-6.94%LLY-1.06%
PTC Therapeutics to buy Sangamo’s ST-920 Fabry gene therapy program for $111 million upfrontPUBT·Aug 12 at 03:02 PMPTCT+3.39%
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board AppointmentSimplywall·Aug 12 at 02:36 AMPTCT+3.39%
